- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01925352
Safety Study of Adenovirus Hepatocyte Growth Factor to Treat Ischemic Heart Disease
August 19, 2013 updated by: zhijian yang, The First Affiliated Hospital with Nanjing Medical University
Phase 2 Study of Adenovirus Hepatocyte Growth Factor for Treatment of Ischemic Heart Disease
To explore the safety and efficiency of adenovirus-hepatocyte growth factor(Ad-HGF) treatment in ischemic heart disease.
Study Overview
Detailed Description
- Ischemic heart disease refers to a group of closely related syndromes by an imbalance between the myocardial oxygen demand and the blood supply.
- Gene therapy offers an attractive alternative to current pharmacologic therapies and may be beneficial in refractory disease. Gene therapy with hepatocyte growth factor induces angiogenesis, decreases apoptosis and leads to protection in the ischemic heart. In this study, we mainly explore the safety and effects of adenovirus hepatocyte growth factor for the treatment of ischemic heart disease.
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Dingguo Zhang, PhD.
- Phone Number: 6640 86-25-83718836
- Email: zhdg0223@aliyun.com
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Recruiting
- Jiangsu Province Hospital
-
Contact:
- Dingguo Zhang, PhD
- Phone Number: 6640 86-25-83718836
- Email: zhdg0223@aliyun.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- person with ischemic heart disease;
- Male or female of 20 to 70 years old;
- No blood perfusion detected in some area of heart using Single-Photon Emission Computed Tomography(SPECT) or Magnetic Resonance Imaging(MRI)
- two or more than two coronary arteries lesions were detected using coronary artery angiography and at least one coronary artery are un-suitable for percutaneous coronary intervention (PCI) or Coronary artery bypass grafting (CABG);Or patients refuse to perform PCI or CABG
- LVEF is ≤45%;
- Patients must sign approved informed consent.
Exclusion Criteria:
- Acute myocardial infarction occured within one week
- CABG performed within 6 months or PCI performed within 3 months
- Patients with systemic active infection
- Blood alanine aminotransferase (ALT)>135mmol/L or blood crea(Cr)>200umol/L or patients with chronic obstructive pulmonary disease (COPD)
- patients with obvious bleeding tendency and blood disease
- patients with malignant tumor or end-stage disease
- patient anticipated life expectancy is less than 12 months
- patient recently attended test drugs or other device research
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ad-HGF
5×10(9)pfu adenovirus hepatocyte growth factor was delivered by transendocardial injection in patients with ischemic heart disease into five left ventricular sites once.
|
5×10(9)pfu adenovirus hepatocyte growth factor was delivered by transendocardial injection into five left ventricular sites.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with death,new myocardial infarction or stroke
Time Frame: 6 months after treatment
|
6 months after treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
left ventricular ejection fraction (LVEF)
Time Frame: 6 months after treatment
|
6 months after treatment
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
tumor markers of blood
Time Frame: 6 months after treatment
|
6 months after treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Zhijian Yang, PhD., The First Affiliated Hospital with Nanjing Medical University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2012
Primary Completion (Anticipated)
December 1, 2015
Study Completion (Anticipated)
December 1, 2015
Study Registration Dates
First Submitted
August 15, 2013
First Submitted That Met QC Criteria
August 16, 2013
First Posted (Estimate)
August 19, 2013
Study Record Updates
Last Update Posted (Estimate)
August 20, 2013
Last Update Submitted That Met QC Criteria
August 19, 2013
Last Verified
August 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Virus Diseases
- Infections
- Arteriosclerosis
- Arterial Occlusive Diseases
- DNA Virus Infections
- Coronary Disease
- Heart Diseases
- Coronary Artery Disease
- Myocardial Ischemia
- Ischemia
- Adenoviridae Infections
- Molecular Mechanisms of Pharmacological Action
- Mitosis Modulators
- Mitogens
Other Study ID Numbers
- HIHD
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischemic Heart Disease
-
Genzyme, a Sanofi CompanyTerminatedIschemic Heart Disease | Ischemic Cardiomyopathy | Ischemic Heart FailureBelgium, France, Germany, Italy, Switzerland, United Kingdom
-
University of AlbertaRecruitingCoronary Artery Disease | Stable Ischemic Heart Disease | Beta-blocker TherapyCanada
-
Gerencia de Atención Primaria, MadridServicio Canario de Salud; Avedis Donabedian Research InstituteCompletedIschemic Heart Disease ChronicSpain
-
Michael SekelaCompletedChronic Ischemic Heart DiseaseUnited States
-
Cardiocentro TicinoTerminatedChronic Ischemic Heart DiseaseSwitzerland
-
Rigshospitalet, DenmarkNot yet recruitingChronic Ischemic Heart DiseaseDenmark
-
University of PecsCompleted
-
The University of Texas Health Science Center,...National Heart, Lung, and Blood Institute (NHLBI); Cardiovascular Cell Therapy...CompletedIschemic Cardiomyopathy | Left Ventricular Dysfunction | Angina | Chronic Ischemic Heart DiseaseUnited States
-
Affiliated Hospital to Academy of Military Medical...Ivy Institute of Stem Cells Co. LtdUnknownHeart Failure | Angina | Chronic Ischemic Heart DiseaseChina
-
University of EdinburghUnknown
Clinical Trials on Ad-HGF
-
The First Affiliated Hospital with Nanjing Medical...UnknownMyocardial Infarction
-
Beijing Northland Biotech. Co., Ltd.RecruitingIschemia | Peripheral Vascular Disease | Arterial Occlusive Disease | UlcersChina
-
Beijing Northland Biotech. Co., Ltd.CompletedIschemia | Peripheral Vascular Disease | Arterial Occlusive Disease | UlcersChina
-
Beijing Northland Biotech. Co., Ltd.RecruitingIschemia | Peripheral Vascular Disease | Arterial Occlusive Disease | UlcersChina
-
AnGes USA, Inc.CompletedIschemia | Peripheral Vascular Disease | Arterial Occlusive DiseaseUnited States
-
Beijing Northland Biotech. Co., Ltd.RecruitingPeripheral Artery DiseaseChina
-
Addpharma Inc.CompletedHypertensionKorea, Republic of
-
Addpharma Inc.Recruiting
-
Addpharma Inc.Not yet recruitingHypertension,Essential
-
AnGes USA, Inc.CompletedIschemia | Peripheral Vascular Disease | Arterial Occlusive Disease | UlcersUnited States